Scott Hansen
18Patents
6h-index
16Co-inventors
55Inventor score
Filing activity: Nov 14, 2012 → Jul 1, 2021
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US9249427B2 | Recombinant HCMV and RHCMV vectors and uses thereof | Emerging Cross-Sectional Technologies | 18 | Active |
| US9783823B2 | Cytomegalovirus vectors enabling control of T cell targeting | Chemistry; Metallurgy | 13 | Active |
| US9982241B2 | Recombinant HCMV and RHCMV vectors and uses thereof | Emerging Cross-Sectional Technologies | 13 | Active |
| US9862972B2 | CMV glycoproteins and recombinant vectors | Emerging Cross-Sectional Technologies | 10 | Active |
| US9541553B2 | CMV glycoproteins and recombinant vectors | Chemistry; Metallurgy | 10 | Active |
| US10101329B2 | CMV glycoproteins and recombinant vectors | Chemistry; Metallurgy | 9 | Active |
| US10688164B2 | CMV vectors comprising microRNA recognition elements | Emerging Cross-Sectional Technologies | 6 | Active |
| US10316334B2 | Cytomegalovirus vectors enabling control of T cell targeting | Chemistry; Metallurgy | 4 | Active |
| US10532099B2 | Cytomegalovirus vectors eliciting T cells restricted by major histocompatibility complex E molecules | Emerging Cross-Sectional Technologies | 4 | Active |
| US10760097B2 | CMV glycoproteins and recombinant vectors | Emerging Cross-Sectional Technologies | 4 | Active |
| US10428118B2 | Human cytomegalovirus comprising exogenous antigens | Emerging Cross-Sectional Technologies | 4 | Active |
| US10995121B2 | Human cytomegalovirus comprising exogenous antigens | Emerging Cross-Sectional Technologies | 1 | Active |
| US11091775B2 | Recombinant cytomegalovirus vectors as vaccines for tuberculosis | Chemistry; Metallurgy | 0 | Active |
| US11834669B2 | Recombinant cytomegalovirus vectors as vaccines for tuberculosis | Chemistry; Metallurgy | 0 | Active |
| US11692012B2 | Human cytomegalovirus comprising exogenous antigens | Emerging Cross-Sectional Technologies | 0 | Active |
| US11091779B2 | Methods and compositions useful in generating non canonical CD8+ T cell responses | Emerging Cross-Sectional Technologies | 0 | Active |
| US11305015B2 | Cytomegalovirus vectors eliciting T cells restricted by major histocompatibility complex E molecules | Emerging Cross-Sectional Technologies | 0 | Active |
| US11266732B2 | Recombinant HCMV and RHCMV vectors and uses thereof | Emerging Cross-Sectional Technologies | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.